SignalChem Lifesciences announces a collaboration with Merck to evaluate the combination of SLC-391, a selective AXL inhibitor, with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with advanced non-small cell lung cancer (NSCLC).

SGD Pharma has introduced an industry-first offering of Type I molded glass vials. These market-driven value propositions represent the latest step in SGD Pharma’s ongoing improvements to its product offers and services.

IONTAS and FairJourney Biologics have announced the identification of neutralizing antibodies, which bind to multiple emerging SARS-CoV-2 variants. This identification has allowed for the development of a panel of therapeutic candidates.

Over two-thirds of Britons – 68% – want an end to animal experiments in medical research in UK labs, a new poll reveals. The YouGov survey showed strong public support for ending animal experiments and replacing them with non-animal alternatives, such as artificial intelligence and using human cells or tissues.

Waters Corporation has introduced a new peptide multi-attribute method (MAM) workflow for the Waters™ BioAccord™ LC-MS System, enabling drug development, manufacturing, and QC scientists to monitor efficacy and safety through the analysis of critical quality attributes (CQAs) of monoclonal antibodies (mAbs) and other protein-based drugs.

CN Bio has announced the commercial launch of its new PhysioMimix™ OOC Multi-Organ MPS which will provide advanced insights into the potential effects of novel therapeutics that were previously only achievable using animal models.

Axol Bioscience Ltd, and CENSO Biotechnologies have announced that the two companies have signed a merger agreement. The new entity will be a provider of product and service solutions in the iPSC-based neuroscience, immune cell, and cardiac modeling for drug discovery and screening markets.

Promega Corporation has released XpressAmp™ Direct Amplification Reagents that facilitate RNA extraction-free sample preparation that is automation-friendly. With this innovation, laboratories testing for COVID-19 have a new tool that enables them to skip the potentially bottlenecked RNA extraction step of the workflow and move directly to polymerase chain reaction (PCR) amplification.

APEIRON Biologics AG, a privately held biotech company developing breakthrough therapies to treat cancer and respiratory conditions, announced today that APN01 (alunacedase alfa) treatment showed statistically significant improvements in specific areas for severely ill COVID-19 patients.

Eppendorf has developed the brand new VisioNize® pipette manager and is on its way towards digitalization in manual pipetting.